Illumina (ILMN) Optics for Genomics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics

ILMN 119.66

-2.3%

11:51 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (26)	5/10/2002 9:10:53 PM
From: mopgcw	Read Replies (1) of 276

Illumina Receives $1.0 Million Phase 2 SBIR Grant From the National Institutes of Health to Develop Matrixed Microarrays Microplate-Compatible Format to Enable Array-Based, Parallel Processing of Thousands of Samples with Reduced Experimental Variability SAN DIEGO--(BW HealthWire)--May 10, 2002-- Illumina, Inc. announced today that it has received a $1.0 million Phase 2 grant from the National Institutes of Health's (NIH) Small Business Innovation Research (SBIR) Program to further develop the Company's BeadArray(TM) technology for parallel processing of array experiments -- an important capability for high-throughput SNP genotyping, RNA profiling, and proteomics applications. Illumina's system is designed to provide reliable and cost-effective multi-sample processing for increasingly advanced microarray-based studies that require the analysis of hundreds to many thousands of samples. Typical microarrays allow many analyses to be carried out simultaneously on a single sample. Illumina's Array of Arrays(TM) format adds another dimension of "parallelism" by allowing many microarray experiments to be conducted at the same time in a microtiter plate format that is a standard in life science laboratories. According to Dr. Mark Chee, Illumina's Vice President of Genomics, "This grant will allow us to develop new, automated systems for generating high-quality data from many samples using our parallel array format. We believe this will enable researchers to accelerate their studies of genetic variation and function and help to catalyze the development of personalized medicine." Illumina (Nasdaq: ILMN; www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. Illumina's technology will have applicability across a wide variety of industries beyond life sciences and pharmaceuticals, including agriculture, food, chemicals and petrochemicals.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next